P4HAS as modifiers of the IGFR pathway and methods of use

Details P4HAS as modifiers of the IGFR pathway and methods of use P4HAS as modifiers of the IGFR pathway and methods of use

2011-02-15

2011-02-15

Cook, Lisa V (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007100, C436S001000, C436S501000, C436S518000, C424S009100, C424S520000, C422S001000, C422S050000, C422S067000, C530S300000, C530S350000

Reexamination Certificate

active

07888048

ABSTRACT:
Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided.

REFERENCES:
patent: WO 01/68868 (2001-09-01), None
patent: WO 02/088363 (2002-11-01), None
patent: WO 03/100008 (2003-12-01), None
Horelli-Kuitunen, et al., “The order and transcriptional orientation of the human COL13A1 and P4HA genes on chromosome 10 long arm determined by high-resolution FISH.”, Genomics, Dec. 1, 1997, vol. 46, No. 2, pp. 299-302.
Sexton, et al., “Trascriptional profiling reveals suppressed erythropoiesis, up-regulated glycosis, and interferon-associated responses in murine malaria.”, Journal of Infectious Diseases, Apr. 1, 2004, vol. 189, No. 7, pp. 1245-1256.
Roguska M A et al.: “An Increase in PROLYL-4-Hydroxylase Activity Occurs During the Retinoic-Acid-Induced Differentiation of Mouse Teratocarcinoma Stem Cell Lines F-9 and P-19,” Journal of Biological Chemistry, (Microfilms), American Society of Biological Chemists, Baltimore, MD, US, vol. 260, No. 26, 1985, pp. 13893-13896.
Guoan Chen et al.: “Proteomic analysis of lung adenocarcinoma: Identification of a highly express set of proteins in tumors,” Clinical Cancer Research, The American Association for Cancer Research, US, vol. 8, No. 7, 2002, pp. 2298-2305.
Nissi Ritva et al.: “Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumors: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts,” ACTA Histochemica, Elsevier, vol. 106, No. 2, May 18, 2004, pp. 111-121.

Affiliated with

Also associated with

Rating

P4HAS as modifiers of the IGFR pathway and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P4HAS as modifiers of the IGFR pathway and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P4HAS as modifiers of the IGFR pathway and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2645269